# OnCo record nct04988295 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04988295/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04988295", "NCT04988295" ;
  schema:name "A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure"@en ;
  schema:alternateName "MARIPOSA-2"@en ;
  schema:description "A phase 3 trial of Lazertinib, Amivantamab, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04988295/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04988295> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-11-17" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> .